eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
EyeCRO Contributes to LUXTURNA® Potency Assay Validation
We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…
eyecro’s First Published Article in Molecular and Cellular Biology
Retinol-Binding Protein 4 Induces Inflammation in Human Endothelial Cells by a NADPH Oxidase- and Nuclear Factor Kappa B-dependent and Retinol-Independent Mechanism Krysten M. Farjoa,#, Rafal A. Farjob, Stacey Halseya, Gennadiy Moiseyeva and Jian-xing Maa aDepartment of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma beyecro LLC, Oklahoma City, Oklahoma ABSTRACT Serum retinol-binding protein…
NIH-Industry Collaboration Advances Gene-Agnostic Treatment for Retinal Disease
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
New Insights into Optic Nerve Injury Treatment with Brain-Derived Neurotrophic Factor (BDNF)
In the article “Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush,” published in Pharmaceuticals, Volume 17, Issue 6 (June 2024), scientists explored the impact of BDNF on retinal structure and visual function. The study focused on rodent models to investigate how BDNF affects retinal ganglion…
eyecro COO Gives Talk at ARVO
“Dr. Rafal Farjo, Chief Operating Officer of eyecro, gives a seminar to Members-in-Training on Transitioning from Academia to a Start-up. At the 2013 Annual meeting of the Association for Research in vision and Ophthalmology in Seattle.”
EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration
“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release
